{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:15:53Z","timestamp":1791908153531,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Den Danske Forskningsfond","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping pharmacological effects, such as suppression of gastric emptying, reduction of glucagon secretion and weight loss in common; however, they also have distinct effects on prandial insulin secretion. Hence, a combination of these two mechanisms is of significant interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we investigated the add-on potential of the dual amylin and calcitonin receptor agonist (DACRA) KBP-089 in combination with the GLP-1 receptor agonist liraglutide as obesity treatment in high-fat diet (HFD) fed rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Increasing doses of KBP-089 and liraglutide alone and in combination were studied with respect to their effects on body weight, food intake and glucose metabolism during a 9-week intervention study conducted in HFD rats. Further, the gastric emptying rate during an oral glucose tolerance was assessed. Treatment with KBP-089 and liraglutide dose-dependently lowered body weight 15% (at 2.5\u2009\u03bcg\/kg\/day) and 7% (at 400\u2009\u03bcg\/kg\/day) in HFD rats, respectively, while the combination resulted in a 21% body weight reduction, which was mirrored by reduction in fat depot sizes. Gastric emptying and glucose metabolism were improved, primarily by KBP-089, although liraglutide led to a reduction in fasting plasma glucagon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DACRAs complement GLP-1 on food intake, body weight, and glucose tolerance indicating the potential for an add-on therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-020-00678-2","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T14:03:18Z","timestamp":1610028198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile"],"prefix":"10.1186","volume":"21","author":[{"given":"Anna Thors\u00f8","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Gydesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"678_CR1","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","volume":"307","author":"KV Andreassen","year":"2014","unstructured":"Andreassen KV, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, Christiansen C, M a K, Henriksen K. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. Am J Physiol Endocrinol Metab. 2014;307:E24\u201333.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"678_CR2","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1210\/jc.2006-2003","volume":"92","author":"L Aronne","year":"2007","unstructured":"Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"678_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, Harper A, Kunesova M, MEJ L, Niskanen L, Rasmussen MF, Rissanen A, Rossner S, Savolainen MJ, Van Gaal L. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843\u201354 England.","journal-title":"Int J Obes (Lond)"},{"key":"678_CR4","doi-asserted-by":"publisher","first-page":"R945","DOI":"10.1152\/ajpregu.00275.2010","volume":"299","author":"NT Bello","year":"2010","unstructured":"Bello NT, Kemm MH, Ofeldt EM, Moran TH. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Integr Comp Physiol. 2010;299:R945-52.","journal-title":"Am J Physiol Integr Comp Physiol."},{"key":"678_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/2040622315620180","volume":"7","author":"J Crane","year":"2016","unstructured":"Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7:92\u2013107.","journal-title":"Ther Adv Chronic Dis"},{"key":"678_CR6","doi-asserted-by":"publisher","first-page":"R856","DOI":"10.1152\/ajpregu.00179.2018","volume":"315","author":"S Duffy","year":"2018","unstructured":"Duffy S, Lutz TA, Boyle CN. Rodent models of leptin receptor deficiency are less sensitive to amylin. Am J Physiol Regul Integr Comp Physiol. 2018;315:R856-65.","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"678_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","volume":"13","author":"K Cusi","year":"2009","unstructured":"Cusi K. Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. Clin Liver Dis. 2009;13:545\u201363.","journal-title":"Clin Liver Dis"},{"key":"678_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, Andreasen AH, Jensen CB, DeFronzo RA. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314:687\u201399 United States.","journal-title":"JAMA"},{"key":"678_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1463-1326.2011.01425.x","volume":"13","author":"M Feigh","year":"2011","unstructured":"Feigh M, Henriksen K, Andreassen KV, Hansen C, Henriksen JE, Christiansen C, Karsdal MA. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes, Obes Metab. 2011;13:911\u201320.","journal-title":"Diabetes, Obes Metab"},{"key":"678_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12325-010-0110-x","volume":"28","author":"A Flint","year":"2011","unstructured":"Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human Glucagon-Like Peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011;28:213\u201326.","journal-title":"Adv Ther"},{"key":"678_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham L, Anis AH. The incidence of co-morbidities related to obesity and overweight : A systematic review and meta-analysis. BMC Public Health. 2009;9:1\u201320.","journal-title":"BMC Public Health"},{"key":"678_CR12","first-page":"2015","volume":"00514","author":"S Gydesen","year":"2016","unstructured":"Gydesen S, Andreassen KV, Hjuler ST, Christensen JM, Karsdal MA, Henriksen K. KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight. Am J Physiol Endocrinol Metab ajpendo. 2016;00514:2015.","journal-title":"Am J Physiol Endocrinol Metab ajpendo."},{"key":"678_CR13","first-page":"2016","volume":"00419","author":"S Gydesen","year":"2017","unstructured":"Gydesen S, Andreassen KV, Hjuler ST, Hellgren LI, Karsdal MA, Henriksen K. Optimization of Tolerability and Efficacy of Dual Amylin and Calcitonin Receptor Agonist, KBP-089, through Dose Escalation and Combination with a GLP-1 Analogue. Am J Physiol - Endocrinol Metab ajpendo. 2017a;00419:2016.","journal-title":"Am J Physiol - Endocrinol Metab ajpendo."},{"key":"678_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bph.13723","volume":"174","author":"S Gydesen","year":"2017","unstructured":"Gydesen S, Hjuler ST, Freving Z, Andreassen KV, Sonne N, Hellgren LI, Karsdal MA, Henriksen K. A novel Dual Amylin and Calcitonin Receptor Agonist (DACRA), KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017b;174:591\u2013602.","journal-title":"Br J Pharmacol"},{"key":"678_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","volume":"366","author":"DW Haslam","year":"2005","unstructured":"Haslam DW, James WPT. Obesity. Lancet (London, England). 2005;366:1197\u2013209 England.","journal-title":"Lancet (London, England)"},{"key":"678_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","volume":"762","author":"ST Hjuler","year":"2015","unstructured":"Hjuler ST, Andreassen KV, Gydesen S, Karsdal MA, Henriksen K. KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration. Eur J Pharmacol. 2015;762:229\u201338.","journal-title":"Eur J Pharmacol"},{"key":"678_CR17","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/oby.21563","volume":"24","author":"ST Hjuler","year":"2016","unstructured":"Hjuler ST, Gydesen S, Andreassen KV, Lund S, Pedersen K, Hellgren LI, Karsdal MA, Henriksen K. The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Increases Insulin Sensitivity and Induces Weight Loss in Rats with Obesity. Obesity. 2016;24:1712\u201322.","journal-title":"Obesity"},{"key":"678_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1124\/jpet.117.241281","volume":"362","author":"ST Hjuler","year":"2017","unstructured":"Hjuler ST, Gydesen S, Andreassen KV, Karsdal MA, Henriksen K. The Dual Amylin- and Calcitonin Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes. J Pharmacol Exp Ther. 2017;362:24\u201330.","journal-title":"J Pharmacol Exp Ther."},{"key":"678_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","volume":"97","author":"M Horowitz","year":"2012","unstructured":"Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:258\u201366 Elsevier Ireland Ltd.","journal-title":"Diabetes Res Clin Pract"},{"key":"678_CR20","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.2337\/db14-1910","volume":"64","author":"JO Jansson","year":"2015","unstructured":"Jansson JO, Palsdottir V. Brain IL-6 - Where amylin and GLP-1 antiobesity signaling congregate. Diabetes. 2015;64:1498\u20139.","journal-title":"Diabetes."},{"key":"678_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","volume":"14","author":"J Jelsing","year":"2012","unstructured":"Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Bjerre Knudsen L. Liraglutide: Short-lived effect on gastric emptying-long lasting effects on body weight. Diabetes, Obes Metab. 2012;14:531\u20138.","journal-title":"Diabetes, Obes Metab"},{"key":"678_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840\u20136.","journal-title":"Nature"},{"key":"678_CR23","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","volume":"62","author":"SE Kanoski","year":"2012","unstructured":"Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology. 2012;62:1916\u201327 Elsevier Ltd.","journal-title":"Neuropharmacology"},{"key":"678_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1089\/dia.2013.0366","volume":"16","author":"DJ Klein","year":"2014","unstructured":"Klein DJ, Battelino T, Chatterjee DJ, Jacobsen LV, Hale PM, Arslanian S. Liraglutide\u2019s Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Technol Ther. 2014;16:679\u201387.","journal-title":"Diabetes Technol Ther"},{"key":"678_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1742-1241.2010.02499.x","volume":"64","author":"LB Knudsen","year":"2010","unstructured":"Knudsen LB. Liraglutide: The therapeutic promise from animal models. Int J Clin Pract. 2010;64:4\u201311 Blackwell Publishing Ltd.","journal-title":"Int J Clin Pract"},{"key":"678_CR26","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.2147\/DDDT.S58459","volume":"9","author":"EE Ladenheim","year":"2015","unstructured":"Ladenheim EE. Liraglutide and obesity: A review of the data so far. Drug Des Devel Ther. 2015;9:1867\u201375.","journal-title":"Drug Des Devel Ther"},{"key":"678_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ijo.2013.149","volume":"38","author":"MEJ Lean","year":"2014","unstructured":"Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, R\u00f6ssner S, Van Gaal L, Astrup A. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes. 2014;38:689\u201397.","journal-title":"Int J Obes"},{"key":"678_CR28","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1038\/s41598-019-44591-8","volume":"9","author":"CG Liberini","year":"2019","unstructured":"Liberini CG, Koch-Laskowski K, Shaulson E, McGrath LE, Lipsky RK, Lhamo R, Ghidewon M, Ling T, Stein LM, Hayes MR. Combined Amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss. Sci Rep. 2019;9:8447.","journal-title":"Sci Rep."},{"key":"678_CR29","doi-asserted-by":"publisher","first-page":"R1855","DOI":"10.1152\/ajpregu.00297.2007","volume":"293","author":"C Mack","year":"2007","unstructured":"Mack C, Wilson J, Athanacio J, Reynolds J, Laugero K, Guss S, Vu C, Roth J, Parkes D. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1855-63.","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"678_CR30","first-page":"385","volume-title":"Davalintide ( AC2307 ), a novel amylin-mimetic peptide : enhanced pharmacological properties over native amylin to reduce food intake and body weight","author":"CM Mack","year":"2010","unstructured":"Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, Roth JD, Smith PA, Gedulin B, Jodka CM, Roland BL, Adams SH, Lwin A, Herich J, Laugero KD, Vu C, Pittner R, Jr JRP. Davalintide ( AC2307 ), a novel amylin-mimetic peptide : enhanced pharmacological properties over native amylin to reduce food intake and body weight; 2010. p. 385\u201395."},{"key":"678_CR31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","volume":"13","author":"CM Mack","year":"2011","unstructured":"Mack CM, Smith PA, Athanacio JR, Xu K, Wilson JK, Reynolds JM, Jodka CM, Lu MGW, Parkes D. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes, Obesity Metab. 2011;13:1105\u201313.","journal-title":"Diabetes, Obesity Metab."},{"key":"678_CR32","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","volume":"20","author":"S Mili\u0107","year":"2014","unstructured":"Mili\u0107 S, Luli\u0107 D, \u0160timac D. Non-alcoholic fatty liver disease and obesity: Biochemical metabolic and clinical presentations. World J Gastroenterol. 2014;20:9330\u20137.","journal-title":"World J Gastroenterol"},{"key":"678_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1210\/jc.2008-1641","volume":"93","author":"WJ Pories","year":"2008","unstructured":"Pories WJ. Bariatric surgery: Risks and rewards. J Clin Endocrinol Metab. 2008;93:89\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"678_CR34","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","volume":"21","author":"RE Ratner","year":"2004","unstructured":"Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus : a 1-year , randomized controlled trial. Diabet Med. 2004;21:1204\u201312.","journal-title":"Diabet Med"},{"key":"678_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2337\/db06-0565","volume":"56","author":"K Raun","year":"2007","unstructured":"Raun K, Von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007;56:8\u201315.","journal-title":"Diabetes"},{"key":"678_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1476-5381.2011.01537.x","volume":"166","author":"JD Roth","year":"2012","unstructured":"Roth JD, Erickson MR, Chen S, Parkes DG. GLP-1R and amylin agonism in metabolic disease: Complementary mechanisms and future opportunities. Br J Pharmacol. 2012;166:121\u201336.","journal-title":"Br J Pharmacol"},{"key":"678_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/DDDT.S3225","volume":"2","author":"G Ryan","year":"2008","unstructured":"Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther. 2008;2:203\u201314.","journal-title":"Drug Des Devel Ther"},{"key":"678_CR38","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/dc08-0029","volume":"31","author":"SR Smith","year":"2008","unstructured":"Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31:1816\u201323.","journal-title":"Diabetes Care"},{"key":"678_CR39","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J Van Can","year":"2014","unstructured":"Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38:784\u201393.","journal-title":"Int J Obes"},{"key":"678_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","volume":"25","author":"T Vilsb\u00f8ll","year":"2008","unstructured":"Vilsb\u00f8ll T, Brock B, Perrild H, Levin K, Lervang H, K\u00f8lendorf K, Krarup T, Schmitz O, Zdravkovic M, Madsbad S. Original Article: Treatment Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008;25:152\u20136.","journal-title":"Diabet Med."},{"key":"678_CR41","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.2337\/dc06-2593","volume":"30","author":"T Vilsb\u00f8ll","year":"2007","unstructured":"Vilsb\u00f8ll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J-P, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care. 2007;30:1608\u201310.","journal-title":"Diabetes Care."},{"key":"678_CR42","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2174\/1381612013397357","volume":"7","author":"C Weyer","year":"2001","unstructured":"Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7:1353\u201373.","journal-title":"Curr Pharm Des"},{"key":"678_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.physbeh.2010.04.012","volume":"101","author":"PY Wielinga","year":"2010","unstructured":"Wielinga PY, Lowenstein C, Muff S, Munz M, Woods SC, Lutz TA. Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol Behav. 2010;101:45\u201352.","journal-title":"Physiol Behav"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-020-00678-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T21:35:57Z","timestamp":1724276157000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-020-00678-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1186\/s12902-020-00678-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-39438\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-39438\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-39438\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All studies were approved by the Danish Animal Inspectorate (approval number: 2016\u201315\u20130201\u2009\u2212\u200900910).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MK and KH own stocks in Nordic Bioscience. MK and KH hold patents on KBPs. All authors are employees of Nordic Bioscience.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}